Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021 DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...

Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...

Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19 DALLAS, Texas, June 23, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it has been granted Fast Track designation by the FDA for...